EW Edwards Lifesciences Corp

Price (delayed)

$96.98

Market cap

$60.3B

P/E Ratio

39.1

Dividend/share

N/A

EPS

$2.48

Enterprise value

$59.95B

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights
The company's EPS has surged by 84% YoY and by 2.9% QoQ
The net income has soared by 81% YoY and by 2.4% from the previous quarter
EW's quick ratio is up by 11% since the previous quarter but it is down by 8% year-on-year

Key stats

What are the main financial stats of EW
Market
Shares outstanding
621.75M
Market cap
$60.3B
Enterprise value
$59.95B
Valuations
Price to earnings (P/E)
39.1
Price to book (P/B)
10.34
Price to sales (P/S)
11.26
EV/EBIT
33.96
EV/EBITDA
31.05
EV/Sales
11.19
Earnings
Revenue
$5.36B
EBIT
$1.77B
EBITDA
$1.93B
Free cash flow
$1.43B
Per share
EPS
$2.48
Free cash flow per share
$2.3
Book value per share
$9.38
Revenue per share
$8.61
TBVPS
$11.14
Balance sheet
Total assets
$8.42B
Total liabilities
$2.58B
Debt
$688.2M
Equity
$5.84B
Working capital
$2.29B
Liquidity
Debt to equity
0.12
Current ratio
3.41
Quick ratio
2.3
Net debt/EBITDA
-0.18
Margins
EBITDA margin
36%
Gross margin
76.6%
Net margin
28.7%
Operating margin
32.6%
Efficiency
Return on assets
18.8%
Return on equity
27.5%
Return on invested capital
33.7%
Return on capital employed
23.6%
Return on sales
33%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
3.59%
1 week
10.47%
1 month
2.58%
1 year
-6.57%
YTD
-25.14%
QTD
-17.62%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$5.36B
Gross profit
$4.1B
Operating income
$1.75B
Net income
$1.54B
Gross margin
76.6%
Net margin
28.7%
The operating income has soared by 90% YoY and by 3.4% from the previous quarter
The net income has soared by 81% YoY and by 2.4% from the previous quarter
The company's operating margin has surged by 58% YoY
The net margin has soared by 51% YoY

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
39.1
P/B
10.34
P/S
11.26
EV/EBIT
33.96
EV/EBITDA
31.05
EV/Sales
11.19
The company's EPS has surged by 84% YoY and by 2.9% QoQ
The price to earnings (P/E) is 21% lower than the 5-year quarterly average of 49.7 and 19% lower than the last 4 quarters average of 48.3
The equity has grown by 25% year-on-year
The stock's price to book (P/B) is 20% less than its last 4 quarters average of 12.9 and 5% less than its 5-year quarterly average of 10.9
The P/S is 20% below the last 4 quarters average of 14.0 but 7% above the 5-year quarterly average of 10.5
EW's revenue is up by 20% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on sales has surged by 53% YoY
EW's return on assets has surged by 53% year-on-year
The company's return on invested capital rose by 46% YoY but it fell by 3.2% QoQ
Edwards Lifesciences's return on equity has increased by 40% YoY but it has decreased by 3.2% QoQ

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The total assets is up by 17% year-on-year
The company's current ratio fell by 11% YoY but it rose by 11% QoQ
The debt is 88% less than the equity
The equity has grown by 25% year-on-year
The company's debt to equity fell by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.